Management of severe asthma – role of monoclonal antibodies
Management of severe asthma – role of monoclonal antibodies Heading link

Authors:
Kaitlin E. Miles, PharmD, BCPS
Clinical Assistant Professor/Academic Detailing Pharmacist
Medication Review and Academic Detailing (MRAD)/Illinois ADVANCE
University of Illinois at Chicago College of Pharmacy
Learning Objectives Heading link
Learning Objectives:
At the completion of this activity, the participant will be able to:
- Explain the pathophysiology of Type 2 inflammation in severe asthma
- Compare the profiles and product information of the monoclonal antibodies for severe asthma
- Review the approach to management of severe asthma as recommended by the Global Initiative for Asthma (GINA)
Activity Information Heading link
Number of Credits Hours | 1.0 contact hour | Fee: | $35.00 |
Release Date: | April 21, 2022 | Expiration Date: | April 14, 2024 |
Go to activity
Modified on July 11, 2022